Justin Sun has refuted reports accusing HTX-linked wallets of sending small, unsolicited USDT transfers to unrelated addresses, describing these claims as fabricated. The controversy has raised questions about compliance but Sun emphasized that the issue does not involve theft. This clarification aims to address concerns and maintain trust in HTX's operations amid growing scrutiny.
The recent controversy involving HTX-linked wallets and USDT transfers provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 24, 2026 01:31 WIB: out of 50 major cryptocurrencies priced, 43 rose and 6 fell today. Notable movers include BNB at Rp13.420.381 with a 2.28% increase and a Pluang order activity split of 55% Sell / 45% Buy, ETC at Rp141.197 up 2.26% with 0% Sell / 100% Buy, and XTZ at Rp5.556 rising 2.21% with 55% Sell / 45% Buy activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
